Grants and Contributions:

Back to search

Title:

Advanced enzymatic activity testing of anti-COVID19 ACE2-based biotherapeutics

Agreement Number:

961435

Agreement Value:

$81,795.00

Agreement Date:

Nov 6, 2020 - Apr 30, 2021

Description:

The SARs-CoV-2 coronavirus enters cells by binding to its plasma membrane receptor, angiotensin-converting enzyme 2 (ACE2). ACE2 is a member of the renin-angiotensin system that degrades the vasoconstrictor and pro-inflammatory peptide angiotensin II (Ang II) to its vasodilator, anti-inflammatory product Ang-(1-7). This Project involves pre-clinical studies of ACE2-Fc variants with potential therapeutic properties against COVID-19. The compounds will be developed to bind and neutralize the SARs-CoV-2 virus, and to exert intrinsic ACE2 activity, thereby reducing detrimental effects of Ang II. Comprehensive testing of ACE2 enzymatic activity for the designed ACE2-Fc variants arising from this collaboration will be performed. Enzymatic activity testing will be done at three levels: 1. Cell-free assays to test ACE2 enzymatic activity. 2. Cell-based assays using kidney proximal tubular cells. 3. In vivo studies, to determine the effects of lead compounds on blood pressure, kidney injury, and plasma/tissue ACE2 activity in mice with Ang II-mediated hypertension.

Organization:

National Research Council Canada

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:

Ottawa, Ontario, CA K1H 8L6

Reference Number:

172-2020-2021-Q3-961435

Agreement Type:

Grant

Report Type:

Grants and Contributions

Recipient Business Number:

886822212

Recipient Type:

Not-for-profit organization or charity

Recipient's Legal Name:

The Ottawa Hospital Research Institute

Federal Riding Name:

Ottawa South

Federal Riding Number:

35077

Program:

Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:

541725